Artal Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Artal Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-50,000	Closed	-$17.2M	–	116
2018 Q1	$17.2M	Hold	50,000	–	–	0.22%	35
2017 Q4	$18.8M	Buy	+50,000	New	+$20.2M	0.28%	31
2017 Q2	–	Sell	-75,000	Closed	-$29.1M	–	116
2017 Q1	$29.1M	Sell	75,000 -105,000	-58%	-$38.9M	0.65%	14
2016 Q4	$66.1M	Buy	180,000 +80,000	+80%	+$30.4M	1.47%	6
2016 Q3	$40.2M	Sell	100,000 -20,000	-17%	-$8.02M	0.8%	11
2016 Q2	$41.9M	Buy	120,000 +90,000	+300%	+$34.7M	0.87%	7
2016 Q1	$10.8M	Buy	+30,000	New	+$12.4M	0.21%	31

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artal Group's REGN Position: Q3 2016 in Review

Artal Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 50,000 shares — an estimated $20.1M sold.

Artal Group first reported a position in REGN in Q2 2016 and held it in 1 quarter. The position peaked at $17.5M in Q2 2016. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

Artal Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Artal Group sold 50,000 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $20.1M.
Artal Group first reported a position in Regeneron Pharmaceuticals in Q2 2016 and held it in 1 quarter.
Artal Group's Regeneron Pharmaceuticals position peaked at $17.5M in Q2 2016.
553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Artal Group's 13F filing for Q3 2016, filed 14 Nov 2016.